ABCB1 and nasal cavity polyp: What’s more, recent studies have indicated that inhibitors of P-glycoprotein exhibit comparable therapeutic effects to oral GCs and biologics in the treatment of nasal polyps[187–189] indicating that P-glycoprotein inhibitory function might serve as alternative drugs to GCs for treating GC-resistant patients with nasal polyps.